SAStefan D. Anker

Stefan D. Anker

*This is an algorithmically generated author record based on publicly available information.

Stefan D. Anker has a total of 57 co-authors. Here are the top co-authors by number of shared publications:

  • Andrew Justin Stewart Coats

    Heart Research Institute, University of Sydney , 7 Eliza St, Newtown, Sydney, NSW 2042

    11 shared publications
  • Mathias Rauchhaus

    From the Applied Cachexia Research Unit (S.D.A., W.D.) of the Department of Cardiology (K.J.O.), Charité, Campus Virchow-Klinikum, Berlin, Germany; Department of Clinical Cardiology (S.D.A., W.D., M.R., R.S., D.F., C.H.D., M.C., W.S., F.L., P.P., A.J.S.C.), NHLI, Imperial College, London, UK; German Heart Institute Berlin (C.K., R.H.), Germany; Department of Biochemistry (M.K.), Royal Brompton Hospital, London, UK; and Discovery Laboratories Inc (R.S.), Doylestown, Pa

    4 shared publications
  • Piotr Ponikowski

    Wroclaw Medical University

    4 shared publications
  • Rakesh Sharma

    From the Applied Cachexia Research Unit (S.D.A., W.D.) of the Department of Cardiology (K.J.O.), Charité, Campus Virchow-Klinikum, Berlin, Germany; Department of Clinical Cardiology (S.D.A., W.D., M.R., R.S., D.F., C.H.D., M.C., W.S., F.L., P.P., A.J.S.C.), NHLI, Imperial College, London, UK; German Heart Institute Berlin (C.K., R.H.), Germany; Department of Biochemistry (M.K.), Royal Brompton Hospital, London, UK; and Discovery Laboratories Inc (R.S.), Doylestown, Pa

    4 shared publications
  • Wolfram Doehner

    From the Applied Cachexia Research Unit (S.D.A., W.D.) of the Department of Cardiology (K.J.O.), Charité, Campus Virchow-Klinikum, Berlin, Germany; Department of Clinical Cardiology (S.D.A., W.D., M.R., R.S., D.F., C.H.D., M.C., W.S., F.L., P.P., A.J.S.C.), NHLI, Imperial College, London, UK; German Heart Institute Berlin (C.K., R.H.), Germany; Department of Biochemistry (M.K.), Royal Brompton Hospital, London, UK; and Discovery Laboratories Inc (R.S.), Doylestown, Pa

    4 shared publications
  • Derek Harrington

    From Cardiac Medicine, National Heart and Lung Institute, Imperial College School of Medicine, London, UK (S.D.A., T.P.C., P.P., D.H., J.W.S., P.A.P.-W., A.J.S.C.); the Department of Internal Medicine III/Cardiology, Martin-Luther-University Halle-Wittenberg, Halle/Saale, Germany (S.D.A.); and the Department of Anesthesiology and Intensive Care Medicine, University Hospital Charité, Humboldt University Berlin, Germany (W.J.K.).

    2 shared publications

Latest Publications

  • Top Cited Papers

    Uric Acid and Survival in Chronic Heart Failure

    by Stefan D. Anker, Wolfram Doehner, Mathias Rauchhaus, Rakesh Sharma, Darrel Francis, Christoph Knosalla, Constantinos H. Davos, Mariantonietta Cicoira, Waqar Shamim, Michel Kemp, et al.

    Background— Serum uric acid (UA) could be a valid prognostic marker and useful for metabolic, hemodynamic, and functional (MFH) staging in chronic heart failure (CHF). Methods and Results— For the derivation study, 112 patients with CHF (age 59±12 years, peak oxygen consumption [V̇ o 2 ] 17±7 mL/kg per minute) were recruited. In separate studies, we validated the prognostic value of UA (n=182) and investigated the relationship between MFH score and the decision to list patients for heart transplantation (n=120). In the derivation study, the best mortality predicting UA cutoff (at 12 months) was 565 μmol/L (9.50 mg/dL) (independently of age, peak V̇ o 2 , left ventricular ejection fraction, diuretic dose, sodium, creatinine, and urea; P P 2 ≤14 mL/kg per min (MFH score 3), 12-month survival was lowest (31%) compared with patients with 2 (64%), 1 (77%), or no (98%, P Conclusions— High serum UA levels are a strong, independent marker of impaired prognosis in patients with moderate to severe CHF. The relationship between serum UA and survival in CHF is graded. MFH staging of patients with CHF is feasible.


    • 1 January 2003
      • Vol. 4  (1) , 2-6

    Anemia in chronic congestive heart failure: frequency, prognosis, and treatment.

    by Martino Crosato, Wolfram Steinborn, Stefan D Anker

    Chronic heart failure (CHF) is a leading cause of morbidity and mortality. Although a precise definition for a cut-off value of hemoglobin level for anemia is still lacking, it has recently been found to be a common complication in CHF, occurring in 10-20% of patients. There are several possible pathogenetic mechanisms for anemia in CHF, and a precise underlying cause is found in only a minority of patients. In CHF, more than 50% of anemia cases are considered to be 'anemia in chronic illness'. In CHF patients, low hemoglobin values directly relate to poor peak oxygen consumption, disabling symptoms, and impaired survival. Recent pilot studies showed that correction of anemia with erythropoietin and iron may lead to improvement in symptoms and exercise capacity. These issues need to be tested in larger, double-blind, randomized, placebo-controlled trials before anemia treatment becomes routine in patients with CHF.


  • The syndrome of cardiac cachexia

    by Stefan D Anker, Rakesh Sharma


  • Top Cited Papers

    Effects of Xanthine Oxidase Inhibition With Allopurinol on Endothelial Function and Peripheral Blood Flow in Hyperuricemic Patients With Chronic Heart Failure

    by Wolfram Doehner, Nina Schoene, Mathias Rauchhaus, Francisco Leyva-Leon, Darrell V. Pavitt, David A. Reaveley, Gerhard Schuler, Andrew J.S. Coats, Stefan D. Anker, Rainer Hambrecht

    Background — In patients with chronic heart failure (CHF), hyperuricemia is a common finding and is associated with reduced vasodilator capacity and impaired peripheral blood flow. It has been suggested that the causal link of this association is increased xanthine oxidase (XO)–derived oxygen free radical production and endothelial dysfunction. We therefore studied the effects of XO inhibition with allopurinol on endothelial function and peripheral blood flow in CHF patients after intra-arterial infusion and after oral administration in 2 independent placebo-controlled studies. Methods and Results — In 10 CHF patients with normal serum uric acid (UA) levels (315±42 μmol/L) and 9 patients with elevated UA (535±54 μmol/L), endothelium-dependent (acetylcholine infusion) and endothelium-independent (nitroglycerin infusion) vasodilation of the radial artery was determined. Coinfusion of allopurinol (600 μg/min) improved endothelium-dependent but not endothelium-independent vasodilation in hyperuricemic patients ( P 120 μmol/L in all patients (mean reduction 217±15 μmol/L, P P =0.027) and legs (+23%, P =0.029). Flow-dependent flow improved by 58% in arms ( P =0.011). Allantoin, a marker of oxygen free radical generation, decreased by 20% after allopurinol treatment ( P r =0.63, P Conclusions — In hyperuricemic CHF patients, XO inhibition with allopurinol improves peripheral vasodilator capacity and blood flow both locally and systemically.


  • Open Access

    Imbalance of catabolic and anabolic pathways in chronic heart failure. Implications for the treatment of cardiac cachexia

    by Stefan D. Anker

    Chronic heart failure (CHF) is a complex metabolic disorder with multiple interactions between the immune, neurohormonal and cardiovascular systems. That the progression of CHF is due to neurohormonal abnormalities is now considered to be established and has led to major therapeutic benefits. Many current therapies are also thought to exert a variety of immunological effects and this has been much less studied. This review aims to discuss interactions between immune pathways and neurohormonal abnormalities relevant to disease progression in CHF and to the development of cardiac cachexia. Cytokines, in particular tumour necrosis factor-a, have many interactive opportunities within a regulatory network of energy metabolism, immune function and neuroendocrine function. Inflammatory cytokines are known to contribute to the progression of CHF, being related to patients’ prognosis. Advanced CHF can be considered to be a state of chronic (low-grade) inflammation and ca tabolism. Anti-cytokine therapy could be successful in patients with proven immune abnormalities as in cardiac cachexia. In addition, anabolic therapies appear to be indicated in cachectic CHF patients. These novel approaches are certainly not without some risk and many of them are very expensive, which may limit their application to certain subgroups of patients. In the future it may not be enough to monitor only the cardiac function of patients; rather, the immune and neurohormonal status of patients may also need to be included to perform a complete assessment. Keywords: Chronic heart failure, cachexia, wasting, hormones, cytokines, endotoxin.


  • Open Access

    Immune and Neurohormonal Pathways in Chronic Heart Failure

    by Rakesh Sharma, Stefan D. Anker

    Chronic heart failure is a complex disorder with interactions among the cardiovascular, immune, and neurohormonal systems. The concept that the progression of heart failure is due to neurohormonal abnormalities has received the greatest attention to date, leading to substantial therapeutic benefits. Although many current therapies are also thought to exert a variety of immunologic effects, this has been much less studied. In this review, the authors discuss a number of interactions among immune pathways and neurohormonal abnormalities relevant to heart failure. Cytokines, in particular tumor necrosis factor‐α, have tremendous interactive opportunities within a regulatory network of energy metabolism, immune function, and neuroendocrine and hormonal function. Inflammatory cytokines are known to contribute to the progression of heart failure, and have been related to patients' prognosis. Advanced heart failure can be considered a state of chronic (low‐grade) inflammation, and there are many reasons to suggest that anticytokine therapy could be successful in these patients. These novel approaches are certainly not without some risk, and many of them are very expensive, which may limit their application to certain subgroups of patients. In the future, it may not be enough to monitor cardiac function alone. Rather, the immune and neurohormonal status of patients may also need to be included in the performance of a complete assessment.


  • Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone

    by Stefan D Anker, Maurizio Volterrani, Claus-Dieter Pflaum, Christian J Strasburger, Karl Josef Osterziel, Wolfram Doehner, Michael B Ranke, Philip A Poole-Wilson, Andrea Giustina, Rainer Dietz, et al.